NCs exhibit higher CMV DNA levels than SCs. (A) Study flow. (B) Schematic representation of CMV DNAemia kinetics in 3 patient groups by CMV clinical phenotypes during the first 100 days posttransplant. CMV DNAemia values and dates were retrieved from electronic medical records for CMV-seropositive allogeneic HCT recipients. CMV DNA levels were monitored twice a week while inpatient and weekly thereafter until day 100. EC (blue) had no evidence of CMV reactivation posttransplant. SCs (purple) had detectable CMV DNAemia but at low DNA levels (typically <200 IU/mL) and experienced self-resolved episodes of DNAemia (ie, without need for antiviral therapy). NCs (black) experienced CMV reactivation at higher DNA levels (>1000 IU/mL) lasting >7 days and received preemptive antiviral therapy. See text and Table 1 for specific time to onset, duration, and CMV DNA levels by patient groups. (C) CMV DNAemia kinetics for the study cohort by patient group. Actual values for initial and peak CMV DNA levels are shown. None of the patients underwent transplant with detectable DNAemia. Initial DNAemia refers to the first detectable DNAemia after transplant. Peak DNAemia refers to the highest CMV DNA value (IU/mL) reached during the first episode of CMV reactivation. Bars correspond to median with IQR for each group. Y-axis corresponds to log₁₀ scale. P value for comparison of peak DNAemia between SC and NC by using Mann-Whitney U test is shown. Seven patients from the NC group who failed to achieve clearance of DNAemia in response to antiviral therapy are not shown here. EC (n = 19); SC (n = 16); NC (n = 14).